# 1. Financial Performance ## A. Key Figures * **Revenue from Operations:** **₹4,001 Cr** Q2 FY26 (+2%) * EBITDA: ₹9,208 Mn (~₹92.08 Cr) (+22.3%) · EBITDA Margin: 23% * Net Profit after Minority Interest: ₹7,651 Mn (+11.1%) * **Gross Margin:** **65%** * R&D Expenses: ₹13.02 Cr (3.3% of revenue) ## B. Revenue Growth * **Record Top-Line Performance:** Q2 revenue reached an all-time high, driven by strong double-digit growth in India, the U.S., and international markets. * **Pune & CDMO Contribution:** H1 revenue from Pune operations, including U.S. and CDMO segments, contributed **₹180–185 Cr**, highlighting regional scaling. ## C. Profit Margins * **Margin Resilience Amid Mix Pressure:** Gross margin held at 65% despite lower API prices and a shift toward lower-margin international business. * **Guided Margin Expansion:** Management expects **100 bps YoY margin improvement**, with planned opex increases already factored into outlook. * **Intangible Asset Impact:** Recent acquisitions added technical know-how, increasing intangible assets and associated amortization costs. ## D. Cash Flow * **Low Cash Tax Burden Ahead:** Despite higher ETR, **over ₹1,500 Cr in MAT credits** will suppress cash tax outflow for the next 1–2 years. ## E. Cost Structure * **Opex Ramping Across Segments:** H2 will see higher operational costs, including **~₹50 Cr/quarter from U.S. operations** and **~₹50 Cr/quarter for Enzene**, as ramp-up phases conclude. * **Elevated Other Expenses:** A sharp rise in other expenses driven by **increased marketing spend** and consolidation of **two new subsidiaries (Bombay Ortho, Adroit)**. * **R&D Rebound Expected:** H1 R&D was below target; spending expected to accelerate in H2 to reach **4–5% of revenue** as filings concentrate in Q4. * **Stable Forward-Looking Opex:** Other expenses projected to stabilize at **₹900–905 Cr/quarter** in Q3 and Q4 across all segments. --- # 2. Product & Launch Performance ## A. Key Figures * **Product Launches:** **4** completed in H1 · **3–4** planned in H2 * **IPM Ranking:** **#2** in new product launches (past 12 months) ## B. U.S. Launches * **Recent U.S. Momentum:** Strong contribution from recent sacubitril/valsartan launch, with valsartan and sacubitril being the top growth drivers in the first half. * **Regulatory & Legal Timing:** U.S. market entry for key products delayed by patent timelines and litigation; Jynarque launch deferred to FY '27–'28 due to ongoing innovator dispute. * **Controlled Market Entry:** Mirabegron will launch only post-patent expiry per settlement agreement, irrespective of third-party litigation outcomes. * **Launch Approval Process:** U.S. approvals expected approximately **2 years** post-filing, reflecting extended regulatory pathway. ## C. India & Global Launches * **Selective Disclosure:** One meaningful launch highlighted in India;其余 deemed immaterial for current disclosure. ## D. Pipeline Progress * **India GLP-1 Advance:** Clinical trial phase completed and expert committee approval secured for GLP-1 diabetes indication; formal Market Authorization pending and expected imminently. --- # 3. Segment & Business Mix ## A. Key Figures * **Domestic Adroit Business:** **₹15 Cr** quarterly run rate, cost breakeven * **B. S. CDMO Revenue (Full Year):** **₹70–80 Cr** expected · **₹15–20 Cr** average quarterly run rate * **U.S. CDMO Revenue (Q3–Q4):** **₹20 Cr** per quarter projected · **₹50 Cr** opex per quarter * **U.S. CDMO YTD Revenue:** **₹40–45 Cr** achieved * **U.S. CDMO Capacity Revenue Potential:** **₹300 Cr** within 12–18 months * **Medtech Revenue (2Q):** **₹5 Cr** (~900 knee replacements) · **₹8–9 Cr** opex · **₹5 Cr EBITDA loss** * **Medtech Opex (Forward):** **₹10–12 Cr** current · potential increase of **₹7–8 Cr** ## B. Domestic Business * **Integration Move:** Adroit business, now at cost breakeven, will be merged into domestic operations, streamlining reporting and signaling operational maturity. * **M&A Focus:** India remains core for acquisitions, prioritizing domestic formulation brands with value-creation potential; Medtech not a near-term acquisition target. ## C. U.S. CDMO Operations * **Revenue Acceleration:** U.S. CDMO business on track for full-year guidance, with Q3–Q4 revenue expected to stabilize at ₹20 Cr per quarter, excluding Pune contributions. * **Growth Upgrade:** U.S. business growth outlook raised to **double digits** from prior mid-single-digit expectations, driven by sacubitril/valsartan launch momentum. * **High-Margin Profile:** CDMO segment delivers **higher gross and EBITDA margins** than corporate average, underpinned by low material costs and development-focused revenue. * **Capacity Utilization Path:** Full revenue potential of ₹300 Cr expected within 12–18 months, entirely from U.S. CDMO development work, with medium-term investment considerations pending. ## D. Medtech & Enzene * **Medtech Loss Position:** Business reported **₹5 Cr EBITDA loss** on ₹5 Cr revenue, with opex exceeding revenue, though path to **FY '28 breakeven** remains intact. * **Controlled Opex Trajectory:** Future Medtech opex increases expected to be **limited to ₹7–8 Cr**, indicating disciplined spending despite international filing costs. --- # 4. Manufacturing & Capacity ## A. Key Figures * **B. S. CDMO Plant Cost Impact:** **INR50–60 Cr** additional OpEx in H2 (starting Q3) * **U.S. Enzene Plant Run Rate:** **INR300 Cr** annualized (12–18 months outlook) * **Pune Plant Quarterly Run Rate:** **INR25–30 Cr** (base) · **INR120 Cr** in Q2 (including U.S. business) ## B. U.S. Plant Output * **Operational Ramp-Up:** U.S. CDMO plant is live, with breakeven expected within **12 to 18 months**; initial focus on maximizing output. * **Asset Utilization Outlook:** U.S. Enzene facility targets **asset turnover of ~1x** within 12–18 months, signaling efficient scale potential. * **Expansion Optionality:** Management sees strong opportunity in U.S. operations, with **scaling and follow-on investments possible in 3–6 months** based on demand. ## C. Pune Facility Run Rate * **Domestic Profitability Achieved:** Pune plant is **EBITDA positive**, reflecting breakeven or better performance in core domestic operations. * **Revenue Contribution Growth:** Q2 revenue from Pune reached **INR120 Cr**, significantly above base run rate due to U.S.-linked volume. --- # 5. Customer & Market Share ## A. Key Figures * **India Sales:** **₹2,766 Cr** (+4%) * **B. S. Sales:** **₹9 Cr** (+28%) * **Non-U.S. Sales:** **₹1 Cr** (+4%) · **30%+** quarterly growth * **Ex-U.S. Constant Currency Growth:** **~28%** (after 4–5% currency gain) ## B. India Market Position * **Market Leadership Achieved:** Alkem ranked **number one in the Acute segment** with outperformance in 6 of 11 therapies, signaling strong competitive positioning. * **Strategic Market Entry:** Bharat Biotech targets a **meaningful share of India’s GLP-1 market**, highlighting confidence in market size and multi-player viability. ## C. Therapy-Wise Growth * **Outperformance Across Core Therapies:** Alkem grew **2x to 5x faster than the market** in anti-infectives, VMN, pain, respiratory, and anti-diabetes (ex-GPL-1), reflecting strong product uptake. * **Sustained Seasonal Tailwind:** Anti-infective demand remains robust, with seasonality extending into 3Q per October IPM data. ## D. International Traction * **High-Growth Ex-U.S. Momentum:** Non-U.S. markets delivered **>30% quarterly growth**, led by Germany and Australia, with outlook for **high teens to nearly 20% annual growth**. --- # 6. Regulatory & Pricing Risks ## A. Key Figures * GST Impact (H2): ₹25–30 Cr per quarter recurring loss from Sikkim facility benefit removal * **One-Time GST Adjustment:** **₹10–12 Cr** trade-related cost in Q1 | ## B. MIP Impact Uncertainty * **Penicillin G MIP Risk:** Potential Minimum Import Price impact remains **highly speculative**; no financial assessment possible until government notifies exact price level. * **Inventory Buffer:** Company is **currently insulated from immediate supply or cost shocks** due to strong inventory coverage. * **C. S. Pricing Pressure:** **Early price erosion observed** for sacubitril, with **further decline expected within 3–6 months** as competition intensifies. ## C. GST & Tax Changes * **Recurring Revenue Impact:** Loss of Sikkim-based GST benefits will **permanently reduce revenue by ₹50–60 Cr H2 onward**, previously booked under other income. * **Operational Resilience:** Company executed **smooth transition** to revised GST framework despite sector-wide disruptions. * **Affordability Benefit:** GST reform viewed as **positive for long-term market access**, even with near-term cost headwinds. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Growth Guidance:** **Double-digit** full-year FY27 (vs. market at 5–8%) * EBITDA Margin Guidance: 19.5% to 20% full-year FY27 (up from prior 19.5% flat) * **B. S. Market Growth:** **10% to 11%** full-year FY27 (low double-digit, net of price erosion) * **Gross Margin:** **64% to 65%** expected for H2 and full year * **Effective Tax Rate (ETR):** **35% to 38%** projected for FY27 (increase post-MAT exit) ## B. Margin Expansion * **Margin Upside Delivery:** EBITDA margin guidance raised despite ongoing investments, with **~50 bps expansion expected this year** and a target of **100 bps annual improvement from FY27 onward**. * **Investment-Grade Discipline:** Planned margin expansion includes spending on MedTech and CDMO; no deviation unless new opportunities arise. * **Near-Term Cost Timing:** Margin pressure muted in H1 due to delayed expense impact from U.S. CDMO plant ramp-up. ## C. Growth Projections * **Sustained Market Outperformance:** Domestic business on track to beat Indian pharma market growth by **100–150 bps**, driven by strong brand momentum and new launches. * **Multi-Year Confidence:** Management affirms growth visibility into **FY28**, supported by improving MedTech revenue and **Enzene scaling to ₹300 Cr annual run rate**. * **Seasonality Normalization:** Current growth trend remains strong and in line with expectations, though future peaks are not forecastable.